Patent 11154603 was granted and assigned to MicroVAX on October, 2021 by the United States Patent and Trademark Office.
A cDNA composition for reducing the virulence of Bp and reduce the cell kill and scope of the infectious disease Burkholderia pseudomallei. (Bp), which encodes fusion proteins comprised of fragments of the extracellular domains of two Bp proteins are attached to the extracellular domain (ecd) of the potent immunostimulatory protein CD40 ligand (CD40L) in order to increase the levels of neutralizing antibodies which will interfere with the function of the extracellular domains of three Bp protein peptide fragments, OMP85, VgrG5 and Hcp-1, in order to protect against a lethal challenge of Bp.